These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 30988165)

  • 1.
    Watanabe S; Tsuchiya K; Nishimura R; Shirasaki T; Katsukura N; Hibiya S; Okamoto R; Nakamura T; Watanabe M
    Mol Cancer Res; 2019 Jul; 17(7):1459-1467. PubMed ID: 30988165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutant p53 gain of function can be at the root of dedifferentiation of human osteosarcoma MG63 cells into 3AB-OS cancer stem cells.
    Di Fiore R; Marcatti M; Drago-Ferrante R; D'Anneo A; Giuliano M; Carlisi D; De Blasio A; Querques F; Pastore L; Tesoriere G; Vento R
    Bone; 2014 Mar; 60():198-212. PubMed ID: 24373920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of glucosylceramide synthase eliminates the oncogenic function of p53 R273H mutant in the epithelial-mesenchymal transition and induced pluripotency of colon cancer cells.
    Hosain SB; Khiste SK; Uddin MB; Vorubindi V; Ingram C; Zhang S; Hill RA; Gu X; Liu YY
    Oncotarget; 2016 Sep; 7(37):60575-60592. PubMed ID: 27517620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Mutant p53-Dependent Embryonic Stem Cell Gene Signature Is Associated with Augmented Tumorigenesis of Stem Cells.
    Koifman G; Shetzer Y; Eizenberger S; Solomon H; Rotkopf R; Molchadsky A; Lonetto G; Goldfinger N; Rotter V
    Cancer Res; 2018 Oct; 78(20):5833-5847. PubMed ID: 30154152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spindle Assembly Checkpoint Inhibition Can Resensitize p53-Null Stem Cells to Cancer Chemotherapy.
    Liu C; Banister CE; Buckhaults PJ
    Cancer Res; 2019 May; 79(9):2392-2403. PubMed ID: 30862715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of potential novel drug resistance mechanisms by genomic and transcriptomic profiling of colon cancer cells with p53 deletion.
    Kadioglu O; Saeed M; Mahmoud N; Azawi S; Mrasek K; Liehr T; Efferth T
    Arch Toxicol; 2021 Mar; 95(3):959-974. PubMed ID: 33515271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutants TP53 p.R273H and p.R273C but not p.R273G enhance cancer cell malignancy.
    Li J; Yang L; Gaur S; Zhang K; Wu X; Yuan YC; Li H; Hu S; Weng Y; Yen Y
    Hum Mutat; 2014 May; 35(5):575-84. PubMed ID: 24677579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cancer-associated, gain-of-function TP53 variant P152Lp53 activates multiple signaling pathways implicated in tumorigenesis.
    Singh S; Kumar M; Kumar S; Sen S; Upadhyay P; Bhattacharjee S; M N; Tomar VS; Roy S; Dutt A; Kundu TK
    J Biol Chem; 2019 Sep; 294(38):14081-14095. PubMed ID: 31366730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the CRISPR/Cas9 directed mutant TP53 gene repairing effect in human prostate cancer cell line PC-3.
    Batır MB; Şahin E; Çam FS
    Mol Biol Rep; 2019 Dec; 46(6):6471-6484. PubMed ID: 31571107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. P53-R273H mutation enhances colorectal cancer stemness through regulating specific lncRNAs.
    Zhao Y; Li Y; Sheng J; Wu F; Li K; Huang R; Wang X; Jiao T; Guan X; Lu Y; Chen X; Luo Z; Zhou Y; Hu H; Liu W; Du B; Miao S; Cai J; Wang L; Zhao H; Ying J; Bi X; Song W
    J Exp Clin Cancer Res; 2019 Aug; 38(1):379. PubMed ID: 31455383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. OCT4B1 promotes cell growth, migration and invasion suppressing sensitivity to οxaliplatin in colon cancer.
    Wen KM; Zhang GH; Li J; Chen ZQ; Cheng YL; Su X; Zeng QL
    Oncol Rep; 2015 Dec; 34(6):2943-52. PubMed ID: 26398480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting mutant TP53 as a potential therapeutic strategy for the treatment of osteosarcoma.
    Tang F; Min L; Seebacher NA; Li X; Zhou Y; Hornicek FJ; Wei Y; Tu C; Duan Z
    J Orthop Res; 2019 Mar; 37(3):789-798. PubMed ID: 30667081
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Gadea G; Arsic N; Fernandes K; Diot A; Joruiz SM; Abdallah S; Meuray V; Vinot S; Anguille C; Remenyi J; Khoury MP; Quinlan PR; Purdie CA; Jordan LB; Fuller-Pace FV; de Toledo M; Cren M; Thompson AM; Bourdon JC; Roux P
    Elife; 2016 Sep; 5():. PubMed ID: 27630122
    [No Abstract]   [Full Text] [Related]  

  • 14. Roles of TP53 gene in the development of resistance to PI3K inhibitor resistances in CRISPR-Cas9-edited lung adenocarcinoma cells.
    Hou J; Cao X; Cheng Y; Wang X
    Cell Biol Toxicol; 2020 Oct; 36(5):481-492. PubMed ID: 32239370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The presence of telomere fusion in sporadic colon cancer independently of disease stage, TP53/KRAS mutation status, mean telomere length, and telomerase activity.
    Tanaka H; Beam MJ; Caruana K
    Neoplasia; 2014 Oct; 16(10):814-23. PubMed ID: 25379018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An N
    Uddin MB; Roy KR; Hosain SB; Khiste SK; Hill RA; Jois SD; Zhao Y; Tackett AJ; Liu YY
    Biochem Pharmacol; 2019 Feb; 160():134-145. PubMed ID: 30578766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss-of-Function but Not Gain-of-Function Properties of Mutant TP53 Are Critical for the Proliferation, Survival, and Metastasis of a Broad Range of Cancer Cells.
    Wang Z; Burigotto M; Ghetti S; Vaillant F; Tan T; Capaldo BD; Palmieri M; Hirokawa Y; Tai L; Simpson DS; Chang C; Huang AS; Lieschke E; Diepstraten ST; Kaloni D; Riffkin C; Huang DCS; Li Wai Suen CSN; Garnham AL; Gibbs P; Visvader JE; Sieber OM; Herold MJ; Fava LL; Kelly GL; Strasser A
    Cancer Discov; 2024 Feb; 14(2):362-379. PubMed ID: 37877779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of TP53 lesions for p53 system functionality and drug resistance in multiple myeloma using an isogenic cell line model.
    Munawar U; Roth M; Barrio S; Wajant H; Siegmund D; Bargou RC; Kortüm KM; Stühmer T
    Sci Rep; 2019 Dec; 9(1):18062. PubMed ID: 31792264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gain of oncogenic function of p53 mutants regulates E-cadherin expression uncoupled from cell invasion in colon cancer cells.
    Roger L; Jullien L; Gire V; Roux P
    J Cell Sci; 2010 Apr; 123(Pt 8):1295-305. PubMed ID: 20332115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical application of oligonucleotide probe array for full-length gene sequencing of TP53 in colon cancer.
    Takahashi Y; Ishii Y; Nagata T; Ikarashi M; Ishikawa K; Asai S
    Oncology; 2003; 64(1):54-60. PubMed ID: 12457032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.